Imatinib mesylate versus allogeneic HSCT for patients with chronic myelogenous leukemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-10000955

Enrollment

Unknown

Registered

2010-07-24

Start date

2001-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myelogenous leukemia

Interventions

A:transplant

B:imatinib

Eligibility

Sex/Gender

All

Age

10 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with chronic myelogenous leukemia in chronic phase, accelerated phase or blast phase enroll in imatinib group or transplant group by their intention

Exclusion criteria

Exclusion criteria: Serious cardiac, pulmonary, hepatic and renal function failure

Design outcomes

Primary

Measure	Time frame
overall survival;	—

Secondary

Measure	Time frame
progression-free survival;	—

Countries

China

Contacts

Public ContactXiaojun Huang

xjhrm@medmail.com.cn+86 10 88326006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026